Short-Term Debt to Equity Ratio: Cognition Therapeutics (CGTX)
Cognition Therapeutics (CGTX) develops treatments against neuronal degeneration without having any products currently on the market. The business relies on external financing, and its metric stands at 0.01. Historical price action on GURU.Markets links these financial aspects to the implementation of IT systems for protein analysis and test automation. However, global political fragmentation and sanctions complicate component logistics and the conduct of international research.
Metric breakdowns and analytics for Cognition Therapeutics Inc. (CGTX)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Cognition Therapeutics|CGTX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Cognition Therapeutics|CGTX - Company Cumulative Debt|Debts to Book Capitalization Cognition Therapeutics Inc.|CGTX - Long-Term Indebtedness|Company Short-Term Debt Cognition Therapeutics|Quick Ratio cogrx.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:Cognition Therapeutics, Inc.
This metric assesses the extent of the company's reliance on short-term borrowings relative to its equity. By analyzing the short-term debt-to-equity ratio, an investor determines liquidity risk and the business's ability to service obligations due within one year. This chart reflects the balance between financial leverage and asset stability. For Cognition Therapeutics (CGTX), a low debt level is critical to ensuring the long-term development of Alzheimer's disease drugs.
Competitor analysis
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio denalitherapeutics.com (DNLI)|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|BHVN - Current Liabilities to Capital|Short-Term Debt to Capital AMLX (Amylyx)|Short-Term Indebtedness to Equity Trevi Corp|PRAX - Short-Term Debt to Equity|AVXL (anavex.com) - Short-Term Debt to Capital Ratio|CBLL: Short-Term Debt to Capital|PRTA - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio ALEC|ANNX (Annexon Biosciences Inc.) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital OMER|Short-Term Debt to Capital Coefficient neurogene.com|Short-Term Debt to Equity AC Immune SA ACIU|Voyager Therapeutics Inc (VYGR) - Current Liabilities to Capital|NMRA - Short-Term Debt to Equity|SCLX (Scilex Holding Company, Inc.) - Short-Term Debt to Capital Ratio|TVGN (Tevogen Bio Holdings) - Short-Term Debt to Equity Ratio|Alpha Cognition Inc. - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio IKT|SAVA (Cassava Sciences Inc) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital ASRT|COYA (coyatherapeutics.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Current Liabilities to Capital|ABOS - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CRVO (CervoMed, Inc.)|ATHE: Short-Term Debt to Capital|Clene (CLNN) - Short-Term Debt to Capital|Short-Term Debt to Equity PepGen Inc|jupiterneurosciences.com - Current Liabilities to Equity|Short-Term Debt to Capital RLMD|ANVS - Current Liabilities to Capital|Grace Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Firefly Neuro AIFF|KLTO: Short-Term Debt to Equity Ratio|NeuroSense Therapeutics - Short-Term Loans to Capital Ratio|RVPH: Short-Term Debt to Capital|MTVA - Short-Term Debt to Capital Coefficient|NRXS (NeurAxis, Inc) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Helius Medical Technologies Inc. (HSDT)|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|Short-Term Debt to Capital Coefficient bionomics.com.au|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|ATHA - Short-Term Debt to Equity Ratio|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Alzamend Neuro, Inc. (ALZN)|CYCN (cyclerion.com) - Short-Term Debt to Equity Ratio|PTIX: Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio KTTA|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BrainStorm Cell Therapeutics Inc. - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|chromocell.com (CHRO) - Current Liabilities to Capital|ELYM: Short-Term Debt to Equity Ratio|ITCI - Short-Term Debt to Capital|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Marinus Pharma - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Capital SAGE|Short-Term Debt to Equity Ratio Synaptogenix Inc. SNPX|Short-Term Debt to Equity Trevena, Inc TRVN|Vigil Neuroscience Inc. (VIGL) - Current Liabilities to Capital|Anew Medical, Inc. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity cerevel.com (CERE)